https://www.coriell.org/1/research/epigenetic-therapies-spore/career-enhancement-program
for immune checkpoint therapy response. Mechanics and sequelae of response to DNMTi may be dependent on mutation status of the tumor suppressor TP53, with missense mutations associated with a NFKB-mediated inflammasome response compared to the type 1 interferon response observed in TP53-wildtype NSCLC. In vitro 2D and 3D
Content Type: Webpage
